US00211Y5069 - Common Stock
ARCA BIOPHARMA INC
NASDAQ:ABIO (4/26/2024, 7:00:00 PM)
3.58
+0.1 (+2.87%)
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Broomfield, Colorado and currently employs 5 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF), in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that the Company is developing for the treatment of AF in patients with heart failure. The firm's Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The rNAPc2 is in a phase IIb clinical trial as a potential treatment for patients hospitalized with COVID-19.
ARCA BIOPHARMA INC
Suite 430, 8001 Arista Place
Broomfield COLORADO 80021
P: 17209402200
CEO: Michael R. Bristow
Employees: 5
Website: https://arcabio.com/
ARCA biopharma just reported results for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ARCA biopharma (NASDAQ:ABIO) just reported results for the first quarter of 202...
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Here you can normally see the latest stock twits on ABIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: